CN110679549B - 一种阿尔茨海默病小鼠模型的构建方法 - Google Patents
一种阿尔茨海默病小鼠模型的构建方法 Download PDFInfo
- Publication number
- CN110679549B CN110679549B CN201911069753.7A CN201911069753A CN110679549B CN 110679549 B CN110679549 B CN 110679549B CN 201911069753 A CN201911069753 A CN 201911069753A CN 110679549 B CN110679549 B CN 110679549B
- Authority
- CN
- China
- Prior art keywords
- tau
- gly
- lys
- ser
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000010173 Alzheimer-disease mouse model Methods 0.000 title claims abstract description 11
- 238000010276 construction Methods 0.000 title abstract description 11
- 102000013498 tau Proteins Human genes 0.000 claims abstract description 106
- 108010026424 tau Proteins Proteins 0.000 claims abstract description 106
- 210000004556 brain Anatomy 0.000 claims abstract description 31
- 239000013598 vector Substances 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 239000007924 injection Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 238000013221 female mouse model Methods 0.000 claims description 2
- 235000021590 normal diet Nutrition 0.000 claims 1
- 230000007170 pathology Effects 0.000 abstract description 49
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 23
- 230000000971 hippocampal effect Effects 0.000 abstract description 10
- 238000010172 mouse model Methods 0.000 abstract description 6
- 241000699670 Mus sp. Species 0.000 description 35
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 15
- 241000700605 Viruses Species 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 11
- 150000001413 amino acids Chemical group 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 210000002569 neuron Anatomy 0.000 description 10
- 241000702421 Dependoparvovirus Species 0.000 description 8
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 8
- 102000057063 human MAPT Human genes 0.000 description 8
- 230000001575 pathological effect Effects 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- PMNHJLASAAWELO-FOHZUACHSA-N Gly-Asp-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PMNHJLASAAWELO-FOHZUACHSA-N 0.000 description 4
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 4
- 108010079364 N-glycylalanine Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108010089804 glycyl-threonine Proteins 0.000 description 4
- 108010050848 glycylleucine Proteins 0.000 description 4
- 108010060857 isoleucyl-valyl-tyrosine Proteins 0.000 description 4
- 108010064235 lysylglycine Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 108010003885 valyl-prolyl-glycyl-glycine Proteins 0.000 description 4
- OINVDEKBKBCPLX-JXUBOQSCSA-N Ala-Lys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OINVDEKBKBCPLX-JXUBOQSCSA-N 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- ZYPWIUFLYMQZBS-SRVKXCTJSA-N Asn-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N ZYPWIUFLYMQZBS-SRVKXCTJSA-N 0.000 description 3
- WZVSHTFTCYOFPL-GARJFASQSA-N Lys-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N)C(=O)O WZVSHTFTCYOFPL-GARJFASQSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- DJDSEDOKJTZBAR-ZDLURKLDSA-N Thr-Gly-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O DJDSEDOKJTZBAR-ZDLURKLDSA-N 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 210000004295 hippocampal neuron Anatomy 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 3
- 108010026333 seryl-proline Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- AXFMEGAFCUULFV-BLFANLJRSA-N (2s)-2-[[(2s)-1-[(2s,3r)-2-amino-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]pentanedioic acid Chemical compound CC[C@@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AXFMEGAFCUULFV-BLFANLJRSA-N 0.000 description 2
- BUANFPRKJKJSRR-ACZMJKKPSA-N Ala-Ala-Gln Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CCC(N)=O BUANFPRKJKJSRR-ACZMJKKPSA-N 0.000 description 2
- ZFXQNADNEBRERM-BJDJZHNGSA-N Ala-Ala-Pro-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 ZFXQNADNEBRERM-BJDJZHNGSA-N 0.000 description 2
- FSBCNCKIQZZASN-GUBZILKMSA-N Ala-Arg-Met Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O FSBCNCKIQZZASN-GUBZILKMSA-N 0.000 description 2
- KIUYPHAMDKDICO-WHFBIAKZSA-N Ala-Asp-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KIUYPHAMDKDICO-WHFBIAKZSA-N 0.000 description 2
- WKOBSJOZRJJVRZ-FXQIFTODSA-N Ala-Glu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WKOBSJOZRJJVRZ-FXQIFTODSA-N 0.000 description 2
- BTBUEVAGZCKULD-XPUUQOCRSA-N Ala-Gly-His Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BTBUEVAGZCKULD-XPUUQOCRSA-N 0.000 description 2
- LMFXXZPPZDCPTA-ZKWXMUAHSA-N Ala-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N LMFXXZPPZDCPTA-ZKWXMUAHSA-N 0.000 description 2
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 2
- HPSVTWMFWCHKFN-GARJFASQSA-N Arg-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O HPSVTWMFWCHKFN-GARJFASQSA-N 0.000 description 2
- GNYUVVJYGJFKHN-RVMXOQNASA-N Arg-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N GNYUVVJYGJFKHN-RVMXOQNASA-N 0.000 description 2
- MJINRRBEMOLJAK-DCAQKATOSA-N Arg-Lys-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N MJINRRBEMOLJAK-DCAQKATOSA-N 0.000 description 2
- LLQIAIUAKGNOSE-NHCYSSNCSA-N Arg-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N LLQIAIUAKGNOSE-NHCYSSNCSA-N 0.000 description 2
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 2
- IARGXWMWRFOQPG-GCJQMDKQSA-N Asn-Ala-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IARGXWMWRFOQPG-GCJQMDKQSA-N 0.000 description 2
- KMCRKVOLRCOMBG-DJFWLOJKSA-N Asn-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC(=O)N)N KMCRKVOLRCOMBG-DJFWLOJKSA-N 0.000 description 2
- IBLAOXSULLECQZ-IUKAMOBKSA-N Asn-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(N)=O IBLAOXSULLECQZ-IUKAMOBKSA-N 0.000 description 2
- VPPXTHJNTYDNFJ-CIUDSAMLSA-N Asp-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N VPPXTHJNTYDNFJ-CIUDSAMLSA-N 0.000 description 2
- BUVNWKQBMZLCDW-UGYAYLCHSA-N Asp-Asn-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BUVNWKQBMZLCDW-UGYAYLCHSA-N 0.000 description 2
- CELPEWWLSXMVPH-CIUDSAMLSA-N Asp-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O CELPEWWLSXMVPH-CIUDSAMLSA-N 0.000 description 2
- VAWNQIGQPUOPQW-ACZMJKKPSA-N Asp-Glu-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VAWNQIGQPUOPQW-ACZMJKKPSA-N 0.000 description 2
- VFUXXFVCYZPOQG-WDSKDSINSA-N Asp-Glu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O VFUXXFVCYZPOQG-WDSKDSINSA-N 0.000 description 2
- LDGUZSIPGSPBJP-XVYDVKMFSA-N Asp-His-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC(=O)O)N LDGUZSIPGSPBJP-XVYDVKMFSA-N 0.000 description 2
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 2
- RKXVTTIQNKPCHU-KKHAAJSZSA-N Asp-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O RKXVTTIQNKPCHU-KKHAAJSZSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000007590 Calpain Human genes 0.000 description 2
- 108010032088 Calpain Proteins 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- RKAQZCDMSUQTSS-FXQIFTODSA-N Gln-Asp-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N RKAQZCDMSUQTSS-FXQIFTODSA-N 0.000 description 2
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 2
- VLOLPWWCNKWRNB-LOKLDPHHSA-N Gln-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O VLOLPWWCNKWRNB-LOKLDPHHSA-N 0.000 description 2
- MTAOBYXRYJZRGQ-WDSKDSINSA-N Glu-Gly-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MTAOBYXRYJZRGQ-WDSKDSINSA-N 0.000 description 2
- JDUKCSSHWNIQQZ-IHRRRGAJSA-N Glu-Phe-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JDUKCSSHWNIQQZ-IHRRRGAJSA-N 0.000 description 2
- CQAHWYDHKUWYIX-YUMQZZPRSA-N Glu-Pro-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O CQAHWYDHKUWYIX-YUMQZZPRSA-N 0.000 description 2
- HMJULNMJWOZNFI-XHNCKOQMSA-N Glu-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N)C(=O)O HMJULNMJWOZNFI-XHNCKOQMSA-N 0.000 description 2
- CQZDZKRHFWJXDF-WDSKDSINSA-N Gly-Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CN CQZDZKRHFWJXDF-WDSKDSINSA-N 0.000 description 2
- AQLHORCVPGXDJW-IUCAKERBSA-N Gly-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CN AQLHORCVPGXDJW-IUCAKERBSA-N 0.000 description 2
- INLIXXRWNUKVCF-JTQLQIEISA-N Gly-Gly-Tyr Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 INLIXXRWNUKVCF-JTQLQIEISA-N 0.000 description 2
- LLZXNUUIBOALNY-QWRGUYRKSA-N Gly-Leu-Lys Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN LLZXNUUIBOALNY-QWRGUYRKSA-N 0.000 description 2
- FGPLUIQCSKGLTI-WDSKDSINSA-N Gly-Ser-Glu Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O FGPLUIQCSKGLTI-WDSKDSINSA-N 0.000 description 2
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 2
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 2
- TTYKEFZRLKQTHH-MELADBBJSA-N His-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O TTYKEFZRLKQTHH-MELADBBJSA-N 0.000 description 2
- FBOMZVOKCZMDIG-XQQFMLRXSA-N His-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N FBOMZVOKCZMDIG-XQQFMLRXSA-N 0.000 description 2
- CYHYBSGMHMHKOA-CIQUZCHMSA-N Ile-Ala-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N CYHYBSGMHMHKOA-CIQUZCHMSA-N 0.000 description 2
- CCHSQWLCOOZREA-GMOBBJLQSA-N Ile-Asp-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCSC)C(=O)O)N CCHSQWLCOOZREA-GMOBBJLQSA-N 0.000 description 2
- QSXSHZIRKTUXNG-STECZYCISA-N Ile-Val-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QSXSHZIRKTUXNG-STECZYCISA-N 0.000 description 2
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 2
- KWTVLKBOQATPHJ-SRVKXCTJSA-N Leu-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N KWTVLKBOQATPHJ-SRVKXCTJSA-N 0.000 description 2
- DLCOFDAHNMMQPP-SRVKXCTJSA-N Leu-Asp-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DLCOFDAHNMMQPP-SRVKXCTJSA-N 0.000 description 2
- LAPSXOAUPNOINL-YUMQZZPRSA-N Leu-Gly-Asp Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O LAPSXOAUPNOINL-YUMQZZPRSA-N 0.000 description 2
- WXUOJXIGOPMDJM-SRVKXCTJSA-N Leu-Lys-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O WXUOJXIGOPMDJM-SRVKXCTJSA-N 0.000 description 2
- REPBGZHJKYWFMJ-KKUMJFAQSA-N Leu-Lys-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N REPBGZHJKYWFMJ-KKUMJFAQSA-N 0.000 description 2
- PWPBLZXWFXJFHE-RHYQMDGZSA-N Leu-Pro-Thr Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O PWPBLZXWFXJFHE-RHYQMDGZSA-N 0.000 description 2
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 2
- AAORVPFVUIHEAB-YUMQZZPRSA-N Lys-Asp-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O AAORVPFVUIHEAB-YUMQZZPRSA-N 0.000 description 2
- DFXQCCBKGUNYGG-GUBZILKMSA-N Lys-Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCCN DFXQCCBKGUNYGG-GUBZILKMSA-N 0.000 description 2
- SPCHLZUWJTYZFC-IHRRRGAJSA-N Lys-His-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(O)=O SPCHLZUWJTYZFC-IHRRRGAJSA-N 0.000 description 2
- IVFUVMSKSFSFBT-NHCYSSNCSA-N Lys-Ile-Gly Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN IVFUVMSKSFSFBT-NHCYSSNCSA-N 0.000 description 2
- MUXNCRWTWBMNHX-SRVKXCTJSA-N Lys-Leu-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O MUXNCRWTWBMNHX-SRVKXCTJSA-N 0.000 description 2
- OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 description 2
- YSPZCHGIWAQVKQ-AVGNSLFASA-N Lys-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN YSPZCHGIWAQVKQ-AVGNSLFASA-N 0.000 description 2
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 2
- RIPJMCFGQHGHNP-RHYQMDGZSA-N Lys-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)N)O RIPJMCFGQHGHNP-RHYQMDGZSA-N 0.000 description 2
- ONGCSGVHCSAATF-CIUDSAMLSA-N Met-Ala-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O ONGCSGVHCSAATF-CIUDSAMLSA-N 0.000 description 2
- WYDFQSJOARJAMM-GUBZILKMSA-N Met-Pro-Asp Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O WYDFQSJOARJAMM-GUBZILKMSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101100480715 Mus musculus Mapt gene Proteins 0.000 description 2
- MPGJIHFJCXTVEX-KKUMJFAQSA-N Phe-Arg-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O MPGJIHFJCXTVEX-KKUMJFAQSA-N 0.000 description 2
- OQTDZEJJWWAGJT-KKUMJFAQSA-N Phe-Lys-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O OQTDZEJJWWAGJT-KKUMJFAQSA-N 0.000 description 2
- HPXVFFIIGOAQRV-DCAQKATOSA-N Pro-Arg-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O HPXVFFIIGOAQRV-DCAQKATOSA-N 0.000 description 2
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 2
- BODDREDDDRZUCF-QTKMDUPCSA-N Pro-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]2CCCN2)O BODDREDDDRZUCF-QTKMDUPCSA-N 0.000 description 2
- RCYUBVHMVUHEBM-RCWTZXSCSA-N Pro-Pro-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RCYUBVHMVUHEBM-RCWTZXSCSA-N 0.000 description 2
- ZMLRZBWCXPQADC-TUAOUCFPSA-N Pro-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 ZMLRZBWCXPQADC-TUAOUCFPSA-N 0.000 description 2
- 108010003201 RGH 0205 Proteins 0.000 description 2
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 2
- TYYBJUYSTWJHGO-ZKWXMUAHSA-N Ser-Asn-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O TYYBJUYSTWJHGO-ZKWXMUAHSA-N 0.000 description 2
- GZBKRJVCRMZAST-XKBZYTNZSA-N Ser-Glu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZBKRJVCRMZAST-XKBZYTNZSA-N 0.000 description 2
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 2
- JLPMFVAIQHCBDC-CIUDSAMLSA-N Ser-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N JLPMFVAIQHCBDC-CIUDSAMLSA-N 0.000 description 2
- FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 2
- NUEHQDHDLDXCRU-GUBZILKMSA-N Ser-Pro-Arg Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NUEHQDHDLDXCRU-GUBZILKMSA-N 0.000 description 2
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 2
- ZSDXEKUKQAKZFE-XAVMHZPKSA-N Ser-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N)O ZSDXEKUKQAKZFE-XAVMHZPKSA-N 0.000 description 2
- FQPQPTHMHZKGFM-XQXXSGGOSA-N Thr-Ala-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O FQPQPTHMHZKGFM-XQXXSGGOSA-N 0.000 description 2
- LMMDEZPNUTZJAY-GCJQMDKQSA-N Thr-Asp-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O LMMDEZPNUTZJAY-GCJQMDKQSA-N 0.000 description 2
- CQNFRKAKGDSJFR-NUMRIWBASA-N Thr-Glu-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O CQNFRKAKGDSJFR-NUMRIWBASA-N 0.000 description 2
- LGNBRHZANHMZHK-NUMRIWBASA-N Thr-Glu-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O LGNBRHZANHMZHK-NUMRIWBASA-N 0.000 description 2
- LHNNQVXITHUCAB-QTKMDUPCSA-N Thr-Met-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O LHNNQVXITHUCAB-QTKMDUPCSA-N 0.000 description 2
- MXDOAJQRJBMGMO-FJXKBIBVSA-N Thr-Pro-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O MXDOAJQRJBMGMO-FJXKBIBVSA-N 0.000 description 2
- MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 2
- PELIQFPESHBTMA-WLTAIBSBSA-N Thr-Tyr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 PELIQFPESHBTMA-WLTAIBSBSA-N 0.000 description 2
- YODDULVCGFQRFZ-ZKWXMUAHSA-N Val-Asp-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O YODDULVCGFQRFZ-ZKWXMUAHSA-N 0.000 description 2
- JAKHAONCJJZVHT-DCAQKATOSA-N Val-Lys-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)N JAKHAONCJJZVHT-DCAQKATOSA-N 0.000 description 2
- VENKIVFKIPGEJN-NHCYSSNCSA-N Val-Met-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N VENKIVFKIPGEJN-NHCYSSNCSA-N 0.000 description 2
- UQMPYVLTQCGRSK-IFFSRLJSSA-N Val-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N)O UQMPYVLTQCGRSK-IFFSRLJSSA-N 0.000 description 2
- RTJPAGFXOWEBAI-SRVKXCTJSA-N Val-Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RTJPAGFXOWEBAI-SRVKXCTJSA-N 0.000 description 2
- 108091060592 XDNA Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 108010016616 cysteinylglycine Proteins 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 2
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 2
- 108010028295 histidylhistidine Proteins 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 108010054155 lysyllysine Proteins 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000010174 APPSwe Methods 0.000 description 1
- WDIYWDJLXOCGRW-ACZMJKKPSA-N Ala-Asp-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WDIYWDJLXOCGRW-ACZMJKKPSA-N 0.000 description 1
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- VENMDXUVHSKEIN-GUBZILKMSA-N Arg-Ser-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VENMDXUVHSKEIN-GUBZILKMSA-N 0.000 description 1
- ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 description 1
- PQKSVQSMTHPRIB-ZKWXMUAHSA-N Asn-Val-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O PQKSVQSMTHPRIB-ZKWXMUAHSA-N 0.000 description 1
- FAEIQWHBRBWUBN-FXQIFTODSA-N Asp-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N)CN=C(N)N FAEIQWHBRBWUBN-FXQIFTODSA-N 0.000 description 1
- YDJVIBMKAMQPPP-LAEOZQHASA-N Asp-Glu-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O YDJVIBMKAMQPPP-LAEOZQHASA-N 0.000 description 1
- ILQCHXURSRRIRY-YUMQZZPRSA-N Asp-His-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)O)N ILQCHXURSRRIRY-YUMQZZPRSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- XTHUKRLJRUVVBF-WHFBIAKZSA-N Cys-Gly-Ser Chemical compound SC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O XTHUKRLJRUVVBF-WHFBIAKZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- FGYPOQPQTUNESW-IUCAKERBSA-N Gln-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N FGYPOQPQTUNESW-IUCAKERBSA-N 0.000 description 1
- RGAOLBZBLOJUTP-GRLWGSQLSA-N Gln-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](CCC(=O)N)N RGAOLBZBLOJUTP-GRLWGSQLSA-N 0.000 description 1
- FFVXLVGUJBCKRX-UKJIMTQDSA-N Gln-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)N)N FFVXLVGUJBCKRX-UKJIMTQDSA-N 0.000 description 1
- HYPVLWGNBIYTNA-GUBZILKMSA-N Gln-Leu-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HYPVLWGNBIYTNA-GUBZILKMSA-N 0.000 description 1
- KPNWAJMEMRCLAL-GUBZILKMSA-N Gln-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N KPNWAJMEMRCLAL-GUBZILKMSA-N 0.000 description 1
- PAOHIZNRJNIXQY-XQXXSGGOSA-N Gln-Thr-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PAOHIZNRJNIXQY-XQXXSGGOSA-N 0.000 description 1
- BBFCMGBMYIAGRS-AUTRQRHGSA-N Gln-Val-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BBFCMGBMYIAGRS-AUTRQRHGSA-N 0.000 description 1
- INGJLBQKTRJLFO-UKJIMTQDSA-N Glu-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O INGJLBQKTRJLFO-UKJIMTQDSA-N 0.000 description 1
- DCBSZJJHOTXMHY-DCAQKATOSA-N Glu-Pro-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DCBSZJJHOTXMHY-DCAQKATOSA-N 0.000 description 1
- DDXZHOHEABQXSE-NKIYYHGXSA-N Glu-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O DDXZHOHEABQXSE-NKIYYHGXSA-N 0.000 description 1
- IWAXHBCACVWNHT-BQBZGAKWSA-N Gly-Asp-Arg Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IWAXHBCACVWNHT-BQBZGAKWSA-N 0.000 description 1
- BEQGFMIBZFNROK-JGVFFNPUSA-N Gly-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)O BEQGFMIBZFNROK-JGVFFNPUSA-N 0.000 description 1
- QITBQGJOXQYMOA-ZETCQYMHSA-N Gly-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CN QITBQGJOXQYMOA-ZETCQYMHSA-N 0.000 description 1
- DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 description 1
- OQQKUTVULYLCDG-ONGXEEELSA-N Gly-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)CN)C(O)=O OQQKUTVULYLCDG-ONGXEEELSA-N 0.000 description 1
- POJJAZJHBGXEGM-YUMQZZPRSA-N Gly-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN POJJAZJHBGXEGM-YUMQZZPRSA-N 0.000 description 1
- ZLCLYFGMKFCDCN-XPUUQOCRSA-N Gly-Ser-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CO)NC(=O)CN)C(O)=O ZLCLYFGMKFCDCN-XPUUQOCRSA-N 0.000 description 1
- DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- YADRBUZBKHHDAO-XPUUQOCRSA-N His-Gly-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C)C(O)=O YADRBUZBKHHDAO-XPUUQOCRSA-N 0.000 description 1
- LVXFNTIIGOQBMD-SRVKXCTJSA-N His-Leu-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O LVXFNTIIGOQBMD-SRVKXCTJSA-N 0.000 description 1
- 101000575685 Homo sapiens Synembryn-B Proteins 0.000 description 1
- PNDMHTTXXPUQJH-RWRJDSDZSA-N Ile-Glu-Thr Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@H](O)C)C(=O)O PNDMHTTXXPUQJH-RWRJDSDZSA-N 0.000 description 1
- LBRCLQMZAHRTLV-ZKWXMUAHSA-N Ile-Gly-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LBRCLQMZAHRTLV-ZKWXMUAHSA-N 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- CIVKXGPFXDIQBV-WDCWCFNPSA-N Leu-Gln-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CIVKXGPFXDIQBV-WDCWCFNPSA-N 0.000 description 1
- KZZCOWMDDXDKSS-CIUDSAMLSA-N Leu-Ser-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KZZCOWMDDXDKSS-CIUDSAMLSA-N 0.000 description 1
- RLZDUFRBMQNYIJ-YUMQZZPRSA-N Lys-Cys-Gly Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)O)N RLZDUFRBMQNYIJ-YUMQZZPRSA-N 0.000 description 1
- GAHJXEMYXKLZRQ-AJNGGQMLSA-N Lys-Lys-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O GAHJXEMYXKLZRQ-AJNGGQMLSA-N 0.000 description 1
- QQPSCXKFDSORFT-IHRRRGAJSA-N Lys-Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN QQPSCXKFDSORFT-IHRRRGAJSA-N 0.000 description 1
- WQDKIVRHTQYJSN-DCAQKATOSA-N Lys-Ser-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N WQDKIVRHTQYJSN-DCAQKATOSA-N 0.000 description 1
- JMNRXRPBHFGXQX-GUBZILKMSA-N Lys-Ser-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JMNRXRPBHFGXQX-GUBZILKMSA-N 0.000 description 1
- SBQDRNOLGSYHQA-YUMQZZPRSA-N Lys-Ser-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SBQDRNOLGSYHQA-YUMQZZPRSA-N 0.000 description 1
- ZUGVARDEGWMMLK-SRVKXCTJSA-N Lys-Ser-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN ZUGVARDEGWMMLK-SRVKXCTJSA-N 0.000 description 1
- GIKFNMZSGYAPEJ-HJGDQZAQSA-N Lys-Thr-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O GIKFNMZSGYAPEJ-HJGDQZAQSA-N 0.000 description 1
- ZVXSESPJMKNIQA-YXMSTPNBSA-N Lys-Thr-Pro-Pro Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 ZVXSESPJMKNIQA-YXMSTPNBSA-N 0.000 description 1
- VWPJQIHBBOJWDN-DCAQKATOSA-N Lys-Val-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O VWPJQIHBBOJWDN-DCAQKATOSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 101100298534 Mus musculus Prnp gene Proteins 0.000 description 1
- 101000598063 Mus musculus Transmembrane protease serine 11D Proteins 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 1
- HJSCRFZVGXAGNG-SRVKXCTJSA-N Pro-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1 HJSCRFZVGXAGNG-SRVKXCTJSA-N 0.000 description 1
- MHHQQZIFLWFZGR-DCAQKATOSA-N Pro-Lys-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O MHHQQZIFLWFZGR-DCAQKATOSA-N 0.000 description 1
- WFIVLLFYUZZWOD-RHYQMDGZSA-N Pro-Lys-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WFIVLLFYUZZWOD-RHYQMDGZSA-N 0.000 description 1
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 1
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 1
- FHJQROWZEJFZPO-SRVKXCTJSA-N Pro-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FHJQROWZEJFZPO-SRVKXCTJSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101100480719 Rattus norvegicus Mapt gene Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- WDXYVIIVDIDOSX-DCAQKATOSA-N Ser-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CCCN=C(N)N WDXYVIIVDIDOSX-DCAQKATOSA-N 0.000 description 1
- QVOGDCQNGLBNCR-FXQIFTODSA-N Ser-Arg-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O QVOGDCQNGLBNCR-FXQIFTODSA-N 0.000 description 1
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 1
- NLOAIFSWUUFQFR-CIUDSAMLSA-N Ser-Leu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O NLOAIFSWUUFQFR-CIUDSAMLSA-N 0.000 description 1
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 description 1
- LRWBCWGEUCKDTN-BJDJZHNGSA-N Ser-Lys-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LRWBCWGEUCKDTN-BJDJZHNGSA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- PURRNJBBXDDWLX-ZDLURKLDSA-N Ser-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CO)N)O PURRNJBBXDDWLX-ZDLURKLDSA-N 0.000 description 1
- LLSLRQOEAFCZLW-NRPADANISA-N Ser-Val-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LLSLRQOEAFCZLW-NRPADANISA-N 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 102100026014 Synembryn-B Human genes 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- BVOVIGCHYNFJBZ-JXUBOQSCSA-N Thr-Leu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O BVOVIGCHYNFJBZ-JXUBOQSCSA-N 0.000 description 1
- KERCOYANYUPLHJ-XGEHTFHBSA-N Thr-Pro-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O KERCOYANYUPLHJ-XGEHTFHBSA-N 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- PGEFRHBWGOJPJT-KKUMJFAQSA-N Tyr-Lys-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O PGEFRHBWGOJPJT-KKUMJFAQSA-N 0.000 description 1
- CPTQYHDSVGVGDZ-UKJIMTQDSA-N Val-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)N CPTQYHDSVGVGDZ-UKJIMTQDSA-N 0.000 description 1
- UEHRGZCNLSWGHK-DLOVCJGASA-N Val-Glu-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UEHRGZCNLSWGHK-DLOVCJGASA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 1
- 244000000001 Virome Species 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 230000007792 alzheimer disease pathology Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011824 transgenic rat model Methods 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种阿尔茨海默病小鼠模型的构建方法，采用基因型FVB‑Fgf14Tg(tetO‑MAPT*P301L)4510Kha/JlwsJ雌性小鼠，于小鼠4月龄时脑注射截短tau蛋白或者表达截短tau蛋白的载体后饲养2‑4个月，所述截短tau蛋白氨基酸序列如SEQ ID NO:1所示。本发明成功构建了阿尔茨海默病小鼠模型，构建的小鼠模型只有海马区出现tau病理，其他脑区未见tau病理，本发明将构建周期缩短至6个月，节省了50％以上的建模时间。
Description
技术领域
本发明属于生物医药领域，具体涉及一种阿尔茨海默病小鼠模型的构建方法
背景技术
阿尔茨海默病(Alzheimer’s Disease，简称AD)，俗称老年痴呆，是老年人中常见的一种神经退行性疾病，表现为学习记忆障碍，失语、失用、失认，人格行为改变等全面性痴呆。AD有两大神经病理学特征：细胞外的由β-淀粉样蛋白(β-amyloid,Aβ)聚积成的淀粉样斑块(amyloid plaques)和细胞内的主要由异常过度磷酸化tau蛋白形成的神经纤维缠结(neurofibrillary tangle,NFT)。迄今为止，针对Aβ的所有临床试验并无明显效果(Iqbal,K.,Liu,F.,Gong,C.X.,2018.Recent developments with tau-based drugdiscovery.Expert Opin Drug Discov 13,399-410.)。越来越多的研究提示，人脑中tau病理传播是导致AD病程进展的关键原因之一，抑制tau病理可能对延缓或阻止AD病理传播起到积极作用(Iqbal et al.,2018)。现有技术从AD患者脑中提取的异常过度磷酸化tau或体外表达重组tau蛋白经肝素诱导形成的聚集物，注射到小鼠脑海马区，诱发小鼠tau蛋白发生类AD样tau病理,并向相关脑区传播，可作为AD的疾病模型小鼠，用于AD相关致病机制研究，药物开发和筛选等(Clavaguera et al.,2009Clavaguera,F.,Bolmont,T.,Crowther,R.A.,Abramowski,D.,Frank,S.,Probst,A.,Fraser,G.,Stalder,A.K.,Beibel,M.,Staufenbiel,M.,Jucker,M.,Goedert,M.,Tolnay,M.,2009.Transmission and spreadingof tauopathy in tra nsgenic mouse brain.Nat Cell Biol 11,909-913.Hu,W.,Zhang,X.,Tung,Y.C.,Xie,S.,Liu,F.,Iqbal,K.,2016.Hyperphosphorylation determines boththe spread and the morphology of tau pathology.Alzheimers Dement 12,1066-1077.)。
现有技术制作AD的tau病理小鼠模型主要有三种方式。第一种方式选用野生型小鼠，如C57/B6J，FVB等品系小鼠。在小鼠4月龄时，注射AD病人脑中提取的病理性tau或体外表达重组的tau聚集物后，需要9-11个月可在小鼠脑中检测到诱发性tau病理。模型制作周期相对较长，共需13至15个月(Hu,W.,Zhang,X.,Tung,Y.C.,Xie,S.,Liu,F.,Iqbal,K.,2016.Hyperphosphorylation determines both the spread and the morphology oftau pathology.Alzheimers Dement 12,1066-1077.)。
第二种方式选择转基因小鼠，如3XTg(美国Jackson实验室小鼠编号034830，基因型B6；129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax)，12个月大时注射AD病人脑中提取的病理性tau后6周，可以检测到诱导性tau病理；其缺点在于模型制作周期仍然过长，超过一年，显然不适合大规模药物筛选(Dai,C.L.,Hu,W.,Tung,Y.C.,Liu,F.,Gong,C.X.,Iqbal,K.,2018.Tau passive immunization blocks seeding and spread of Alzheimerhyperphosphorylated Tau-induced pathology in 3x Tg-AD mice.Alzheimers ResTher 10,13.)。
第三种方式是在鼠脑中表达人的tau蛋白突变体，制作转基因小鼠，如P301L(Taconic公司小鼠编号2508，基因型Tg(Prnp-MAPT*P301L)JNPL3Hlmc)和P301S(美国Jackson实验室小鼠编号008169，基因型B6；C3-Tg(Prnp-MAPT*P301S)PS19Vle/J)等。这些小鼠分别在4.5月龄和6月龄时就产生tau病理，但因为转基因在全脑的神经元均有表达，后期无法观察海马神经元中tau病理向其他神经元的扩散传播。(Terwel,D.,Lasrado,R.,Snauwaert,J.,Vandeweert,E.,Van Haesendonck,C.,Borghgraef,P.,Van Leuven,F.,2005.Changed conformation of mutant Tau-P301L underlies the moribundtauopathy,absent in progressive,nonlethal axonopathy of Tau-4R/2N transgenicmice.J Biol Chem 280,3963-3973.)
因此建立一个造模时间短，且仅在海马神经元中产生tau病理的小鼠模型是现有科研工作者们仍然需要攻克的难题。
发明内容
本发明针对现有技术不足，通过选择特定的tau蛋白以及小鼠，获得的模型鼠海马区出现tau病理，其他脑区未见tau病理，且成功缩短了造模周期。
本发明具体技术方案如下：
一种阿尔茨海默病小鼠模型的构建方法，采用基因型FVB-Fgf14Tg(tetO-MAPT*P301L)4510Kha/JlwsJ雌性小鼠，于小鼠4月龄时脑注射截短tau蛋白或者表达截短tau蛋白的载体后饲养2-4个月(优选饲养2个月)，所述截短tau蛋白氨基酸序列如SEQ ID NO:1所示。
上述基因型FVB-Fgf14Tg(tetO-MAPT*P301L)4510Kha/JlwsJ小鼠为美国Jac kson实验室小鼠，编号为15815(基因型FVB-Fgf14Tg(tetO-MAPT*P301L)4510Kha/JlwsJ)。该转基因小鼠含有tet反应元件和小鼠prion蛋白启动子序列，指导人tau蛋白突变体tau P301L表达。在没有tet诱导时，该小鼠的prion蛋白启动子使大脑中tau P301L中度表达，但不会导致tau病理。
本发明所述氨基酸序列如SEQ ID NO:1所示的人截短tau蛋白为全长tau蛋白氨基酸序列的第151-391位的蛋白片段。
上述方法，小鼠4月龄时脑注射截短tau蛋白或者表达截短tau蛋白的载体后采用常规的饲养方式自由摄取水和食物。室温20度，12小时光照/黑暗循环环境。
上述方法，优选表达人截短tau蛋白的载体为腺病毒，进一步优选为腺病毒AAV9载体。
本发明另一目的在于提供氨基酸序列如SEQ ID NO:1所示的截短tau蛋白在快速构建阿尔茨海默病小鼠模型中的应用，采用基因型FVB-Fgf14Tg(tetO-MAPT*P301L)4510Kha/JlwsJ雌性小鼠造模。
阿尔茨海默病(Alzheimer s disease AD)是一种神经退行性疾病其主要病理的特征有神经细胞内的神经元纤维缠结NFTs、神经细胞外的淀粉样斑块SP和大量神经细胞的凋亡丧失等。NFTs的主要组成成份即是Tau蛋白。目前已知AD病人脑中tau蛋白K44-E45，R230-T231(Park SY,Ferreira A.The generation of a 17kDa neurotoxic fragment:analternative mechanism by which tau mediates beta-amyloid-inducedneurodegeneration.J Neurosci.2005；25:5365–5375),A152-T153,E391-I392,D421-S422(B.Kovacech1 and M.Novak1,Tau Truncation is a Productive PosttranslationalModification of Neurofibrillary Degeneration in Alzheimer’s Disease CurrentAlzheimer Research,2010,7,708-716)等位点可以在不同蛋白酶水解下发生截断。在阿尔茨海默氏症病人的脑脊液中存在Tau蛋白的截短片段。Park等用Aβ处理AD小鼠的原代培养神经元，激活神经元细胞中的Calpain水解Tau产生17kD的Tau蛋白片段(tau45-230)，并诱导原代培养神经元细胞的凋亡。耿俊华选用果蝇作为模式生物，依据Tau蛋白上潜在的Calpain水解位点将Tau蛋白截短成不同的截短片段Tau1-44、Tau45-441、Tau45-230和Tau231-441。(人源Tau蛋白截短片段转基因果蝇模型的建立，生命科学研究，第19卷第2期)。CN03816647.X公开了N端和C端双重截短tau分子，所述分子相对于含四重复的tau43而言截短至少前236个N端氨基酸和至少后45个C端氨基酸。又如Norbert Zilka公开了构建人截短tau蛋白151-391的转基因大鼠，但该转基因大鼠tau病理仅发生在脑干和小脑深部核团，而并未发生在AD病变相关的海马区和大脑皮层。
目前人们对tau蛋白截短体的功能研究很有限，几乎没有使用tau蛋白截短体构建阿尔茨海默病小鼠模型的研究，现有技术在阿尔茨海默病小鼠模型的构建上还一直未有突破。
本发明考察了tau蛋白、tau蛋白截短体tau1-150、tau392-441、tau151-391对野生型FVB和转基因FVB-Fgf14Tg(tetO-MAPT*P301L)4510Kha/JlwsJ小鼠的阿尔茨海默病模型的构建效果。结果显示tau蛋白、tau蛋白截短体1-150、tau392-441均不能在基因型FVB-Fgf14Tg(tetO-MAPT*P301L)4510Kha/JlwsJ雌性小鼠中诱导tau病理；tau151-391不能在FVB野生型小鼠中诱导tau病理。仅有采用基因型FVB-Fgf14Tg(tetO-MAPT*P301L)4510Kha/JlwsJ雌性小鼠，于小鼠4月龄时脑注射tau151-391或者表达人截短tau蛋白的载体，成功快速获得阿尔茨海默病小鼠模型(脑海马区注射病毒AAV9-Syn promoter-tau151-391，使海马区神经元在腺相关病毒AAV9载体介导下，表达人tau蛋白截断体151-391，诱导tau病理产生。该模型于小鼠4月龄时进行脑注射，6月龄可在脑中检测到诱导性tau病理，而应的雄性小鼠，同样注射该病毒，6月龄未能检测到tau病理)。本发明将tau病理模型的构建周期缩短至6个月，节省了50％以上的时间。且采用定点注射，只有海马区出现tau病理，其他脑区未见tau病理。
附图说明
图1.为本发明所述tau病理模型构建流程图。
图2为使用tau151-391蛋白构建阿尔茨海默病雌性小鼠模型与对照组的病理切片。(图2A和2B为生理盐水组，图2C和2D为AAV9-tau151-391病毒组，B图和D图分别为A图和C图的放大图，图中箭头指出处为AT8染色)。
图3为使用tau全长、tau1-150、tau392-441注射15815雌性鼠脑后的阴性病理切片。(图3A为AAV9-tau全长组，图3B为AAV9-tau1-150组，图3C为AAV9-tau392-441组)。
图4为使用tau151-391注射15815雄性和野生型FVB鼠脑后的阴性病理切片。(图4A为15815雄鼠组，图4B为野生型FVB组)。
具体实施方式
实施例1阿尔茨海默病小鼠模型的构建
分别构建整合人tau蛋白截短体tau151-391、tau1-150、tau392-441和tau蛋白的病毒载体。tau151-391蛋白氨基酸序列如SEQ ID NO:1，所示，DNA序列如SEQ ID NO:2所示；tau1-150蛋白氨基酸序列如SEQ ID NO:3，所示，DNA序列如SEQ ID NO:4所示；tau392-441蛋白氨基酸序列如SEQ ID NO:5，所示，DNA序列如SEQ ID NO:6所示；tau蛋白氨基酸序列如SEQ ID NO:7，所示，DNA序列如SEQ ID NO:8所示。
构建hSyn promoter-MCS-EGFP-3FLAG-SV40 PolyA病毒载体，整合入人tau蛋白全长及各截短体的相应DNA序列，包装腺相关病毒AAV9。
根据人tau蛋白截短体tau151-391、tau1-150、tau392-441和tau蛋白DNA序列为模板，设计引物如下：
tau151-391引物序列：
151-391F：5’-ccggaattcactgccacaccgcgggg-3’(SEQ ID NO:9)
151-391R：5’-cgcggatcctcactccgccccgtggtctg-3’(SEQ ID NO:10)
tau1-150引物序列
Tau1-150F：5’-ccggaattcatggctgagccccgcca-3’(SEQ ID NO:11)
Tau1-150R：5’-cgcggatcctcactccgccccgtggtctg-3’(SEQ ID NO:12)
tau392-441引物序列
tau392-441F：5’-ccggaattcatcgtgtacaagtcgccagtg-3’(SEQ ID NO:13)
tau392-441R：5’-cgcggatcctcacaaaccctgcttggc-3’(SEQ ID NO:14)
tau蛋白全长引物序列
Tau-F：同tau1-150F(SEQ ID NO:11)
Tau-R：同tau392-441R(SEQ ID NO:14)
1.载体构建
A.以人cDNA为模板扩增目的片段
PCR体系：
PCR反应条件：
向50μl PCR产物中加入10μl 6×DNA Loading buffer，1％琼脂糖凝胶进行电泳，120V，40min。分别切胶回收tau151-391、tau1-150、tau392-441和tau全长DNA的PCR产物片段，测定DNA浓度。
B.PCR片段与载体酶切连接
PCR产物酶切体系：
载体酶切体系：
37℃水浴4小时，向50μl酶切产物中加入10μl 6×DNA Loading buffer，1％琼脂糖凝胶进行电泳，120V，40min。分别切胶回收tau151-391、tau1-150、tau392-441和tau全长DNA的片段和载体片段，测定DNA浓度。
C.酶切产物连接：
16℃过夜。
D.连接产物转化至大肠杆菌中扩增，提取后测序鉴定，取正确载体进行质粒大量抽提，并调整各质粒浓度为1μg/μl。
E.AAV-293细胞转染
将AAV-293细胞种于T75细胞培养瓶，加入10mL含10％胎牛血清(FBS)的DMEM培养基。细胞生长至80％-90％密度时，进行转染。
转染后72小时收集细胞。
F.病毒收集和提纯
将包装好病毒颗粒的细胞连同上清一起收集到15mL离心管，1000rpm/min离心3分钟，分离细胞和上清，分别收集。细胞用1mL PBS重悬，反复冻融4次裂解细胞。10000rpm离心去除细胞碎片，取上清和细胞培养的上清混合，0.45μm滤器过滤杂质。加入1/2体积1MNaCl，10％PEG8000，混合均与后置于4度过夜。12000rpm离心2小时，去上清，将病毒沉淀以适量PBS重悬，0.22μm滤器过滤除菌。加入终浓度50U/ml Benzonase核酸酶，37℃孵育30分钟消化残留DNA。0.45μm滤器过滤得AAV病毒粗提物。
病毒粗提物中加入CsCl至密度1.41g/ml,175000g离心24小时，收取不同密度的样品，测定滴度后收集富含AAV颗粒的组分。重复该步骤一次。
将收集的AAV病毒颗粒装入100kDa透析袋，4℃透析脱盐过夜，分别获得纯化的病毒AAV9-tau151-391、AAV9-tau1-150、AAV9-tau392-441和AAV9-tau。2.小鼠脑注射AAV9-Syn promoter-tau151-391病毒
FVB-Fgf14Tg(tetO-MAPT*P301L)4510Kha/JlwsJ小鼠购于美国jackson实验室，编号为15815。随机分为以下7组：1.15815雌性小鼠注射生理盐水；2.15815雌性小鼠注射AAV9-tau151-391；3.15815雌性小鼠注射AAV9-tau全长；4.15815雌性小鼠注射AAV9-tau1-150；5.15815雌性小鼠注射AAV9-tau392-441；6.15815雄性小鼠注射AAV9-tau151-391；7.野生型FVB雌性小鼠注射AAV9-tau151-391；每组3只。
4月龄15815雌性小鼠麻醉后，以前囟为原点，向右1.8-2.0mm，后2.4-2.6mm，深1.66-1.70mm区域注射上述病毒3μL，注射速度1μL/min。注射完成后停针2min，让注射液被脑组织充分吸收。将小鼠置于保温垫上至苏醒后，转至正常饲养至6月龄，处死小鼠，进行病理检测。
实施例2鼠脑tau病理检测
将不同组注射病毒的15815小鼠大脑矢状位40μM厚组织切片进行PBS清洗，含0.5％Triton-X 100的PBS进行透膜处理，5％山羊血清封闭液封闭30min，针对磷酸化tau(tau病理)的特异性抗体mouse-AT8 1:1000 4度孵育过夜，PBS清洗3次，Alexa-555荧光标记的抗小鼠二抗室温避光孵育2hr，加入1:5000Hochest孵育15min，PBS清洗三次，贴片封片。荧光显微镜检测tau病理。结果如图2-4所示，结果显示15815雌性小鼠4月龄时进行脑注射AAV9-tau151-391，6月龄时用Ser202/Thr205位点磷酸化tau的特异性抗体AT8染色标记tau病理，低倍镜下可见海马区部分神经元显示明显的AT8染色，而皮层区域没有AT8染色神经元，说明病毒仅在海马区有效诱导tau病理的产生，同时不累及其他脑区(图2C)。放大图片后，40倍镜下可见AT8染色的磷酸化tau在神经元胞体和突触中大量堆积，信号明显增强，与文献报道的tau病理吻合，进一步说明该模型成功诱导tau病理的产生(图2D)。而对照组小鼠4月龄时脑注射生理盐水，6月龄时海马区和皮层AT8染色呈阴性，均未检测到tau病理(图2A、B)，说明15815雌性小鼠脑注射AAV9-tau151-391后产生的tau病理确由病毒注射引起，而非年龄增长而出现的自然现象。
15815雌性小鼠4月龄时脑注射AAV9-tau全长(图3A)，AAV9-tau1-150(图3B)或AAV9-tau392-441(图3C)，6月龄时海马区AT8抗体染色呈阴性，未检测到tau病理，说明只有tau151-391这一截短体才能在注射后2月内特异性诱发tau病理，而tau全长、tau1-150或tau392-441均无法达到这种效果。
15815雄性小鼠注射AAV9-tau151-391(图4A)，野生型FVB雌性小鼠注射AAV9-tau151-391(图4B)，6月龄时海马区AT8抗体染色呈阴性，均未能检测到tau病理，说明15815雌性小鼠对AAV9-tau151-391尤其敏感，是构建该tau病理模型的适宜小鼠品系。
实施例3.本发明所述小鼠tau病理模型的应用举例
(1)筛选可抑制tau病理的基因。
构建靶基因腺相关病毒载体，注射入4月龄15815小鼠海马区，使靶基因高表达。2周后，同一位置注射AAV9-tau151-391病毒，诱导tau病理产生。6月龄时，取鼠脑进行免疫荧光，比较注射靶基因病毒和对照病毒的鼠脑tau病理强度(tau病理特异性抗体mouse-AT8阳性细胞的数目)，判断靶基因是否影响tau病理产生，从而筛选出可有效抑制tau病理的基因。
(2)筛选可抑制tau病理的药物
4月龄15815小鼠海马区注射AAV9-tau151-391病毒，诱导tau病理产生。注射后第二天，通过腹腔注射或灌胃给小鼠施加相应浓度的药物，持续1个月。6月龄时，取鼠脑进行免疫荧光，比较给药组和对照组之间tau病理强度(tau病理特异性抗体mouse-AT8阳性细胞的数目)，判断药物是否影响tau病理传播，从而筛选出可有效抑制tau病理的药物。
序列表
<110> 南通大学
<120> 一种阿尔茨海默病小鼠模型的构建方法
<160> 14
<170> SIPOSequenceListing 1.0
<210> 1
<211> 241
<212> PRT
<213> 人(human)
<400> 1
Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys Gly Gln Ala
1 5 10 15
Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro Ala Pro Lys Thr Pro
20 25 30
Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly Asp Arg Ser Gly Tyr Ser
35 40 45
Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg Thr Pro Ser
50 55 60
Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys Val Ala Val Val Arg
65 70 75 80
Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser Arg Leu Gln Thr Ala
85 90 95
Pro Val Pro Met Pro Asp Leu Lys Asn Val Lys Ser Lys Ile Gly Ser
100 105 110
Thr Glu Asn Leu Lys His Gln Pro Gly Gly Gly Lys Val Gln Ile Ile
115 120 125
Asn Lys Lys Leu Asp Leu Ser Asn Val Gln Ser Lys Cys Gly Ser Lys
130 135 140
Asp Asn Ile Lys His Val Pro Gly Gly Gly Ser Val Gln Ile Val Tyr
145 150 155 160
Lys Pro Val Asp Leu Ser Lys Val Thr Ser Lys Cys Gly Ser Leu Gly
165 170 175
Asn Ile His His Lys Pro Gly Gly Gly Gln Val Glu Val Lys Ser Glu
180 185 190
Lys Leu Asp Phe Lys Asp Arg Val Gln Ser Lys Ile Gly Ser Leu Asp
195 200 205
Asn Ile Thr His Val Pro Gly Gly Gly Asn Lys Lys Ile Glu Thr His
210 215 220
Lys Leu Thr Phe Arg Glu Asn Ala Lys Ala Lys Thr Asp His Gly Ala
225 230 235 240
Glu
<210> 2
<211> 723
<212> DNA
<213> 人(human)
<400> 2
atcgccacac cgcggggagc agcccctcca ggccagaagg gccaggccaa cgccaccagg 60
attccagcaa aaaccccgcc cgctccaaag acaccaccca gctctggtga acctccaaaa 120
tcaggggatc gcagcggcta cagcagcccc ggctccccag gcactcccgg cagccgctcc 180
cgcaccccgt cccttccaac cccacccacc cgggagccca agaaggtggc agtggtccgt 240
actccaccca agtcgccgtc ttccgccaag agccgcctgc agacagcccc cgtgcccatg 300
ccagacctga agaatgtcaa gtccaagatc ggctccactg agaacctgaa gcaccagccg 360
ggaggcggga aggtgcagat aattaataag aagctggatc ttagcaacgt ccagtccaag 420
tgtggctcaa aggataatat caaacacgtc ccgggaggcg gcagtgtgca aatagtctac 480
aaaccagttg acctgagcaa ggtgacctcc aagtgtggct cattaggcaa catccatcat 540
aaaccaggag gtggccaggt ggaagtaaaa tctgagaagc ttgacttcaa ggacagagtc 600
cagtcgaaga ttgggtccct ggacaatatc acccacgtcc ctggcggagg aaataaaaag 660
attgaaaccc acaagctgac cttccgcgag aacgccaaag ccaagacaga ccacggggcg 720
gag 723
<210> 3
<211> 150
<212> PRT
<213> 人(human)
<400> 3
Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1 5 10 15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
20 25 30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
35 40 45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
50 55 60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
65 70 75 80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
85 90 95
Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
100 105 110
Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Ala Arg Met Val
115 120 125
Ser Lys Ser Lys Asp Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Gly
130 135 140
Ala Asp Gly Lys Thr Lys
145 150
<210> 4
<211> 450
<212> DNA
<213> 人(human)
<400> 4
atggctgagc cccgccagga gttcgaagtg atggaagatc acgctgggac gtacgggttg 60
ggggacagga aagatcaggg gggctacacc atgcaccaag accaagaggg tgacacggac 120
gctggcctga aagaatctcc cctgcagacc cccactgagg acggatctga ggaaccgggc 180
tctgaaacct ctgatgctaa gagcactcca acagcggaag atgtgacagc acccttagtg 240
gatgagggag ctcccggcaa gcaggctgcc gcgcagcccc acacggagat cccagaagga 300
accacagctg aagaagcagg cattggagac acccccagcc tggaagacga agctgctggt 360
cacgtgaccc aagctcgcat ggtcagtaaa agcaaagacg ggactggaag cgatgacaaa 420
aaagccaagg gggctgatgg taaaacgaag 450
<210> 5
<211> 50
<212> PRT
<213> 人(human)
<400> 5
Ile Val Tyr Lys Ser Pro Val Val Ser Gly Asp Thr Ser Pro Arg His
1 5 10 15
Leu Ser Asn Val Ser Ser Thr Gly Ser Ile Asp Met Val Asp Ser Pro
20 25 30
Gln Leu Ala Thr Leu Ala Asp Glu Val Ser Ala Ser Leu Ala Lys Gln
35 40 45
Gly Leu
50
<210> 6
<211> 153
<212> DNA
<213> 人(human)
<400> 6
atcgtgtaca agtcgccagt ggtgtctggg gacacgtctc cacggcatct cagcaatgtc 60
tcctccaccg gcagcatcga catggtagac tcgccccagc tcgccacgct agctgacgag 120
gtgtctgcct ccctggccaa gcagggtttg tga 153
<210> 7
<211> 441
<212> PRT
<213> 人(human)
<400> 7
Met Ala Glu Pro Arg Gln Glu Phe Glu Val Met Glu Asp His Ala Gly
1 5 10 15
Thr Tyr Gly Leu Gly Asp Arg Lys Asp Gln Gly Gly Tyr Thr Met His
20 25 30
Gln Asp Gln Glu Gly Asp Thr Asp Ala Gly Leu Lys Glu Ser Pro Leu
35 40 45
Gln Thr Pro Thr Glu Asp Gly Ser Glu Glu Pro Gly Ser Glu Thr Ser
50 55 60
Asp Ala Lys Ser Thr Pro Thr Ala Glu Asp Val Thr Ala Pro Leu Val
65 70 75 80
Asp Glu Gly Ala Pro Gly Lys Gln Ala Ala Ala Gln Pro His Thr Glu
85 90 95
Ile Pro Glu Gly Thr Thr Ala Glu Glu Ala Gly Ile Gly Asp Thr Pro
100 105 110
Ser Leu Glu Asp Glu Ala Ala Gly His Val Thr Gln Ala Arg Met Val
115 120 125
Ser Lys Ser Lys Asp Gly Thr Gly Ser Asp Asp Lys Lys Ala Lys Gly
130 135 140
Ala Asp Gly Lys Thr Lys Ile Ala Thr Pro Arg Gly Ala Ala Pro Pro
145 150 155 160
Gly Gln Lys Gly Gln Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro
165 170 175
Pro Ala Pro Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser Gly
180 185 190
Asp Arg Ser Gly Tyr Ser Ser Pro Gly Ser Pro Gly Thr Pro Gly Ser
195 200 205
Arg Ser Arg Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys
210 215 220
Lys Val Ala Val Val Arg Thr Pro Pro Lys Ser Pro Ser Ser Ala Lys
225 230 235 240
Ser Arg Leu Gln Thr Ala Pro Val Pro Met Pro Asp Leu Lys Asn Val
245 250 255
Lys Ser Lys Ile Gly Ser Thr Glu Asn Leu Lys His Gln Pro Gly Gly
260 265 270
Gly Lys Val Gln Ile Ile Asn Lys Lys Leu Asp Leu Ser Asn Val Gln
275 280 285
Ser Lys Cys Gly Ser Lys Asp Asn Ile Lys His Val Pro Gly Gly Gly
290 295 300
Ser Val Gln Ile Val Tyr Lys Pro Val Asp Leu Ser Lys Val Thr Ser
305 310 315 320
Lys Cys Gly Ser Leu Gly Asn Ile His His Lys Pro Gly Gly Gly Gln
325 330 335
Val Glu Val Lys Ser Glu Lys Leu Asp Phe Lys Asp Arg Val Gln Ser
340 345 350
Lys Ile Gly Ser Leu Asp Asn Ile Thr His Val Pro Gly Gly Gly Asn
355 360 365
Lys Lys Ile Glu Thr His Lys Leu Thr Phe Arg Glu Asn Ala Lys Ala
370 375 380
Lys Thr Asp His Gly Ala Glu Ile Val Tyr Lys Ser Pro Val Val Ser
385 390 395 400
Gly Asp Thr Ser Pro Arg His Leu Ser Asn Val Ser Ser Thr Gly Ser
405 410 415
Ile Asp Met Val Asp Ser Pro Gln Leu Ala Thr Leu Ala Asp Glu Val
420 425 430
Ser Ala Ser Leu Ala Lys Gln Gly Leu
435 440
<210> 8
<211> 1326
<212> DNA
<213> 人(human)
<400> 8
atggctgagc cccgccagga gttcgaagtg atggaagatc acgctgggac gtacgggttg 60
ggggacagga aagatcaggg gggctacacc atgcaccaag accaagaggg tgacacggac 120
gctggcctga aagaatctcc cctgcagacc cccactgagg acggatctga ggaaccgggc 180
tctgaaacct ctgatgctaa gagcactcca acagcggaag atgtgacagc acccttagtg 240
gatgagggag ctcccggcaa gcaggctgcc gcgcagcccc acacggagat cccagaagga 300
accacagctg aagaagcagg cattggagac acccccagcc tggaagacga agctgctggt 360
cacgtgaccc aagctcgcat ggtcagtaaa agcaaagacg ggactggaag cgatgacaaa 420
aaagccaagg gggctgatgg taaaacgaag atcgccacac cgcggggagc agcccctcca 480
ggccagaagg gccaggccaa cgccaccagg attccagcaa aaaccccgcc cgctccaaag 540
acaccaccca gctctggtga acctccaaaa tcaggggatc gcagcggcta cagcagcccc 600
ggctccccag gcactcccgg cagccgctcc cgcaccccgt cccttccaac cccacccacc 660
cgggagccca agaaggtggc agtggtccgt actccaccca agtcgccgtc ttccgccaag 720
agccgcctgc agacagcccc cgtgcccatg ccagacctga agaatgtcaa gtccaagatc 780
ggctccactg agaacctgaa gcaccagccg ggaggcggga aggtgcagat aattaataag 840
aagctggatc ttagcaacgt ccagtccaag tgtggctcaa aggataatat caaacacgtc 900
ccgggaggcg gcagtgtgca aatagtctac aaaccagttg acctgagcaa ggtgacctcc 960
aagtgtggct cattaggcaa catccatcat aaaccaggag gtggccaggt ggaagtaaaa 1020
tctgagaagc ttgacttcaa ggacagagtc cagtcgaaga ttgggtccct ggacaatatc 1080
acccacgtcc ctggcggagg aaataaaaag attgaaaccc acaagctgac cttccgcgag 1140
aacgccaaag ccaagacaga ccacggggcg gagatcgtgt acaagtcgcc agtggtgtct 1200
ggggacacgt ctccacggca tctcagcaat gtctcctcca ccggcagcat cgacatggta 1260
gactcgcccc agctcgccac gctagctgac gaggtgtctg cctccctggc caagcagggt 1320
ttgtga 1326
<210> 9
<211> 26
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 9
ccggaattca ctgccacacc gcgggg 26
<210> 10
<211> 29
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
cgcggatcct cactccgccc cgtggtctg 29
<210> 11
<211> 26
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 11
ccggaattca tggctgagcc ccgcca 26
<210> 12
<211> 29
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 12
cgcggatcct cactccgccc cgtggtctg 29
<210> 13
<211> 30
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 13
ccggaattca tcgtgtacaa gtcgccagtg 30
<210> 14
<211> 27
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 14
cgcggatcct cacaaaccct gcttggc 27
Claims (5)
1.一种阿尔茨海默病小鼠模型的构建方法，其特征在于采用基因型 FVB-Fgf14T g(tetO-MAPT*P301L)4510Kha/JlwsJ 雌性小鼠，于小鼠4月龄时脑注射截短tau 蛋白或者表达截短tau蛋白的载体后饲养 2-4个月，所述截短tau蛋白氨基酸序 列如 SEQ ID NO:1 所示，脑注射位置为：以前囟为原点，向右1.8-2.0mm，后2.4-2.6mm，深1.66-1.70mm区域。
2.根据权利要求 1 所述的方法，其特征在于所述小鼠4月龄时脑注射截短 tau蛋白或者表达截短 tau 蛋白的载体后正常饮食饲养2个月。
3.根据权利要求 1 所述的方法，其特征在于所述表达截短tau蛋白的载体为腺病毒。
4.根据权利要求 1 所述的方法，其特征在于所述表达截短tau蛋白的载体为腺病毒AAV9 载体。
5.氨基酸序列如 SEQ ID NO:1 所示的截短 tau 蛋白在快速构建阿尔茨海默病小鼠模型中的应用，其特征在于采用基因型 FVB-Fgf14Tg(tetO-MAPT*P301L)4510 Kha/JlwsJ雌性小鼠造模。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911069753.7A CN110679549B (zh) | 2019-11-05 | 2019-11-05 | 一种阿尔茨海默病小鼠模型的构建方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911069753.7A CN110679549B (zh) | 2019-11-05 | 2019-11-05 | 一种阿尔茨海默病小鼠模型的构建方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110679549A CN110679549A (zh) | 2020-01-14 |
| CN110679549B true CN110679549B (zh) | 2021-08-20 |
Family
ID=69115937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911069753.7A Active CN110679549B (zh) | 2019-11-05 | 2019-11-05 | 一种阿尔茨海默病小鼠模型的构建方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110679549B (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112189624A (zh) * | 2020-09-08 | 2021-01-08 | 山东第一医科大学(山东省医学科学院) | 一种利用受体基因沉默技术构建和鉴定女性ad模型的方法 |
| CN113430230A (zh) * | 2021-06-24 | 2021-09-24 | 南通大学 | tau截断体蛋白在诱导tau病理聚集中的应用 |
| CN113876785B (zh) * | 2021-08-26 | 2023-03-14 | 南通大学 | P-3Fax-Neu5Ac的新的药物用途 |
| CN115125244A (zh) * | 2022-05-14 | 2022-09-30 | 吉林大学 | 构建阿尔兹海默症的兔模型方法 |
| CN114903010B (zh) * | 2022-05-19 | 2024-06-07 | 暨南大学 | 神经退行性疾病模型的构建方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1545868A (zh) * | 2003-12-17 | 2004-11-17 | 暨南大学 | 阿尔茨海默病动物模型的制备方法 |
| CN1668745A (zh) * | 2002-07-12 | 2005-09-14 | 阿克松神经科学研究和发展股份有限公司 | 表达阿耳茨海默氏tau蛋白的转基因动物 |
| CN1964720A (zh) * | 2004-04-23 | 2007-05-16 | 巴克研究所 | 阿尔茨海默病的转基因模型及其在治疗多种神经变性疾病中的应用 |
| CN102058619A (zh) * | 2010-12-08 | 2011-05-18 | 山西医科大学 | 一种阿尔茨海默病复合动物模型的制备方法 |
| CN108135986A (zh) * | 2015-08-13 | 2018-06-08 | 纽约大学 | 对于Tau的截短的Asp421表位特异性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途 |
| CN110028583A (zh) * | 2019-05-07 | 2019-07-19 | 温州医科大学 | 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008140639A2 (en) * | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
-
2019
- 2019-11-05 CN CN201911069753.7A patent/CN110679549B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1668745A (zh) * | 2002-07-12 | 2005-09-14 | 阿克松神经科学研究和发展股份有限公司 | 表达阿耳茨海默氏tau蛋白的转基因动物 |
| CN1545868A (zh) * | 2003-12-17 | 2004-11-17 | 暨南大学 | 阿尔茨海默病动物模型的制备方法 |
| CN1964720A (zh) * | 2004-04-23 | 2007-05-16 | 巴克研究所 | 阿尔茨海默病的转基因模型及其在治疗多种神经变性疾病中的应用 |
| CN102058619A (zh) * | 2010-12-08 | 2011-05-18 | 山西医科大学 | 一种阿尔茨海默病复合动物模型的制备方法 |
| CN108135986A (zh) * | 2015-08-13 | 2018-06-08 | 纽约大学 | 对于Tau的截短的Asp421表位特异性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途 |
| CN110028583A (zh) * | 2019-05-07 | 2019-07-19 | 温州医科大学 | 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用 |
Non-Patent Citations (4)
| Title |
|---|
| "P301L突变tau蛋白转基因动物模型及其应用";马登磊 等;《中国比较医学杂志》;20180130;第28卷(第1期);第123-128页 * |
| "Truncated tau from sporadic Alzheimer’s disease suffices to drive neurofibrillary degeneration in vivo";Norbert Zilka et. al.;《FEBS Letters》;20060626;第580卷(第15期);第3582-3588页 * |
| "人源Tau蛋白截短片段转基因果蝇模型的建立";耿俊华;《生命科学研究》;20150430;第19卷(第2期);第95-99页、第113页 * |
| "阿尔茨海默病基因工程模型鼠的研究现状";尹芳 等;《医学综述》;20180120;第24卷(第2期);第241-247页、第253页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110679549A (zh) | 2020-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110679549B (zh) | 一种阿尔茨海默病小鼠模型的构建方法 | |
| JP2023087019A (ja) | 調節性ポリヌクレオチド | |
| JP2023093461A (ja) | ハンチントン病治療組成物および方法 | |
| US20150225741A1 (en) | Vectors for delivery of light sensitive proteins and methods of use | |
| CN116650668A (zh) | 使用基因疗法以推迟疾病发生和发展同时提供认知保护来治疗神经变性疾病的方法 | |
| JP7273730B2 (ja) | 神経セロイドリポフスチン症のための遺伝子療法 | |
| US20200046853A1 (en) | Compositions and methods specifically targeting the apolipoprotein e4 (apoe4) and uses thereof in apoe4 associated conditions | |
| Golenkina et al. | Analysis of clusterin gene (CLU/APOJ) polymorphism in Alzheimer’s disease patients and in normal cohorts from Russian populations | |
| CN102037136A (zh) | 用于诊断、预防和/或护理特征为β-淀粉和/或淀粉样物质在人和/或动物器官和组织中异常沉积的人和/或动物病理的产物及它们的应用、和用于确定这种病理风险的筛选方法 | |
| JP7101656B2 (ja) | Ｒｄｈ１２が関与する疾患及び疾病を治療する方法及び組成物 | |
| US20230399642A1 (en) | Compositions and methods of treating huntington's disease | |
| CN113957095A (zh) | 一种用于构建阿尔兹海默症动物模型的构建方法及其核酸组合物和应用 | |
| TW202221125A (zh) | 用於治療與葡萄糖神經醯胺酶β缺陷相關之神經病症的組合物及方法 | |
| CN113134076A (zh) | 一种利用转录因子再生具备功能的视网膜神经节细胞的方法 | |
| Chacko et al. | CRISPR-Cas9 in Alzheimer’s disease: Therapeutic trends, modalities, and challenges | |
| Besançon et al. | Missense mutation in exon 11 (codon 378) of the presenilin‐1 gene in a French family with early‐onset Alzheimer's disease and transmission study by mismatch enhanced allele specific amplification | |
| Liu et al. | Identification of an α‐l‐iduronidase (IDUA) M1T mutation in a Chinese family with autosomal recessive mucopolysaccharidosis I | |
| Isomura et al. | Cloning and Mapping of a Novel Human cDNA Homologous to DROER, the Enhancer of theDrosophila melanogasterRudimentary Gene | |
| CN110622921B (zh) | 阿尔茨海默病病变区FoxG1过表达小鼠模型的构建方法及应用 | |
| JP2022533451A (ja) | アルツハイマー病のための遺伝子治療 | |
| KR102177174B1 (ko) | Pde6b 유전자가 결손된 망막 변성 동물 모델 및 이의 제조 방법 | |
| Patel et al. | Identification of novel retinal pericyte-targeting rAAV vectors through directed evolution | |
| CN114350659B (zh) | elovl4b基因突变视网膜感光神经元病变斑马鱼模型的构建方法 | |
| WO2023164964A1 (zh) | 一种用于治疗脑损伤的基因工程药物及其制备方法 | |
| US11895993B2 (en) | Method of producing a novel animal model for tauopathies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |